Modality
Cell Therapy
MOA
FGFRi
Target
CGRP
Pathway
mTOR
ObesityADPKDRB
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Feb 2027
Phase 1Current
NCT03309826
857 pts·RB
2018-02→2025-10·Completed
NCT06559603
917 pts·Obesity
2017-06→2027-02·Completed
1,774 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-106mo agoPh2 Data· RB
2027-02-0410mo awayPh2 Data· Obesity
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2025-10-10 · 6mo ago
RB
Ph2 Data
2027-02-04 · 10mo away
Obesity
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03309826 | Phase 1/2 | RB | Completed | 857 | DAS28 |
| NCT06559603 | Phase 1/2 | Obesity | Completed | 917 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |